Does Ozempic Cause Constipation? The Mechanism and the Fix

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Key Takeaways

• STEP 1 reported constipation in roughly 24% of semaglutide 2.4 mg users versus 11% on placebo
• The mechanism is slowed gut transit plus reduced food bulk plus reduced fluid intake
• Unlike nausea, constipation does not fully resolve with continued treatment and usually requires active management
• First-line management: hydration (2 to 3 liters daily), gradual fiber increase, osmotic laxatives like polyethylene glycol
• Severe constipation with abdominal pain, distension, or vomiting requires medical evaluation to rule out ileus or obstruction

Direct answer

Yes. Semaglutide slows gastric and intestinal transit, which combined with reduced food intake and often reduced fluid intake produces constipation in roughly one in four patients. STEP 1 showed 24% incidence on the 2.4 mg dose versus 11% on placebo. The condition is uncomfortable but rarely dangerous and responds well to a combination of hydration, gradual fiber increase, and osmotic laxatives. Constipation tends to persist throughout treatment rather than self-resolve, so ongoing management is usually needed.

Table of contents

1. The trial numbers
2. Why GLP-1 medications cause constipation
3. The hidden hydration problem
4. The fiber math
5. Osmotic laxatives, the gentlest option
6. Magnesium and stimulant laxatives
7. The role of physical activity
8. Constipation vs more serious conditions
9. Tirzepatide constipation: similar or different?
10. Decision framework
11. FAQ
12. Sources

The trial numbers

STEP 1 (Wilding et al., NEJM 2021) reported constipation as one of the most frequent adverse events:

Adverse event	Semaglutide 2.4 mg (n=1306)	Placebo (n=655)
Nausea	44.2%	17.4%
Diarrhea	31.5%	15.9%
Vomiting	24.8%	6.6%
Constipation	23.4%	11.3%
Abdominal pain	20.0%	10.2%

Constipation ranks fourth in frequency but tends to be the most persistent GI symptom. Nausea, diarrhea, and vomiting often improve with continued treatment. Constipation does not.

SURMOUNT-1 showed similar constipation rates with tirzepatide, ranging from 11% to 17% depending on dose. The lower rate in tirzepatide trials may reflect protocol differences or actual molecular differences in gut motility effects.

Why GLP-1 medications cause constipation

Three converging mechanisms:

Mechanism 1: Slowed gastric and intestinal transit. Semaglutide acts on GLP-1 receptors throughout the gut. The most prominent effect is delayed gastric emptying, which is the same mechanism that produces satiety and nausea. The medication also slows transit through the small intestine and colon, giving more time for water to be reabsorbed from stool, which makes it harder and drier.

Mechanism 2: Reduced food volume. Eating less means less stool bulk. The colon needs a certain volume of intraluminal content to trigger reflexive peristalsis. Below that threshold, transit slows further. Patients on aggressive caloric restriction may go from 2,500 calories of food daily to 1,000, with proportional reduction in stool volume.

Mechanism 3: Reduced fluid intake. Appetite suppression often comes with reduced thirst perception. Patients can be mildly dehydrated for weeks without recognizing it. The reduced food water (most food is 50 to 80% water) compounds the deficit. The colon's job of reabsorbing water from stool becomes more efficient when the body is short on fluid, producing harder stool.

The three mechanisms are additive. Addressing one without the others often produces partial relief.

The hidden hydration problem

Patients often underestimate how much their fluid intake drops with appetite suppression. A typical pre-treatment day might include:

• 32 oz of beverages (coffee, water, juice with meals, etc.)
• 2 to 3 liters of water content from food (especially fruits, vegetables, soups)
• Total: roughly 3 to 4 liters fluid intake

An early-titration day might include:

• 20 oz of beverages (less coffee, fewer drinks with meals)
• 1 liter of water from food (smaller meals, less variety)
• Total: roughly 1.5 to 2 liters

A 1.5 to 2 liter daily fluid deficit compounds over days into meaningful dehydration. The colon responds by reabsorbing more water from stool, which dries and hardens it.

The intervention is direct: target 2 to 3 liters of intentional fluid intake daily, on top of whatever comes from food. Water, herbal tea, broth, and electrolyte solutions all count. Coffee and tea count partially (mild diuretic effect). Alcohol does not count.

The fiber math

The average American adult eats 15 to 17 grams of fiber daily. The dietary recommendation is 25 grams for women and 38 grams for men. Most people are already short.

On a GLP-1 medication with reduced total food intake, fiber consumption can drop to 8 to 12 grams per day even with similar food composition. Below this threshold, stool bulk becomes inadequate to drive normal transit.

Fiber sources to consider:

Food	Serving	Fiber (g)
Psyllium husk (Metamucil)	1 tbsp	5-7
Chia seeds	2 tbsp	10
Oatmeal	1 cup cooked	4
Black beans	1/2 cup	7-8
Raspberries	1 cup	8
Avocado	1/2 medium	7
Pear with skin	1 medium	5-6
Whole grain bread	1 slice	2-3

Practical strategy: add psyllium husk 1 to 2 tablespoons daily, mixed in water or smoothie. This provides 5 to 14 grams of soluble fiber, well tolerated by most people. Increase gradually over 1 to 2 weeks. Drink an extra 8 ounces of water with each fiber dose.

Caveat: fiber without adequate water makes constipation worse. The two interventions must go together.

Osmotic laxatives, the gentlest option

Polyethylene glycol 3350 (MiraLAX, Glycolax) is the first-line laxative for GLP-1 constipation. It works by drawing water into the colon, softening stool, and producing easier passage without stimulating gut motility.

Why it suits GLP-1 patients well:

• Does not work by stimulating contractions, which could conflict with the medication's mechanism
• Safe for daily long-term use; not habit-forming
• Predictable, gentle effect with minimal cramping
• Available over the counter
• Inexpensive

Typical dose: 17 grams (one capful) dissolved in 8 oz of water once daily. Effect typically appears within 24 to 48 hours. Can be adjusted up to 17 grams twice daily for inadequate response, or down to 8 to 10 grams once stable.

Magnesium-based osmotic laxatives are an alternative: magnesium citrate 200 to 400 mg daily, or magnesium oxide 400 to 800 mg daily. The advantage is that magnesium is also a useful mineral; the disadvantage is potential for excess magnesium in patients with kidney impairment.

Magnesium and stimulant laxatives

Magnesium citrate is reasonable as a primary or adjunct laxative. Many GLP-1 patients are also low in magnesium due to reduced food intake, so daily supplementation has dual benefit.

Stimulant laxatives (senna, bisacodyl) work by directly stimulating gut motility. They are useful for occasional rescue when polyethylene glycol or magnesium is insufficient, but daily long-term use can lead to dependence and reduced natural motility.

Reasonable approach:

• Daily: polyethylene glycol 17 g + adequate fiber + hydration
• If inadequate after 1 to 2 weeks: add magnesium citrate 200 to 400 mg at night
• Rescue (every few weeks): senna 17.2 mg at bedtime or bisacodyl 5 mg
• Avoid daily stimulants for more than 1 to 2 weeks at a time

Linaclotide (Linzess) and other prescription motility agents are sometimes used for severe cases that do not respond to OTC measures. These typically require specialist consultation.

The role of physical activity

Physical activity stimulates gut motility through multiple mechanisms including increased intra-abdominal pressure during movement, autonomic nervous system activation, and reduced visceral fat that mechanically compresses the colon.

Even modest activity helps:

• 30 minutes of walking daily improves transit in most patients
• The post-meal walk (15 minutes after dinner) takes advantage of the natural gastrocolic reflex
• Resistance training has mild additional benefit through abdominal muscle engagement
• Sedentary patients tend to have more severe constipation regardless of medication

For patients who become more sedentary on a GLP-1 (often due to fatigue in early titration), addressing the activity drop can resolve a meaningful fraction of the constipation problem.

Constipation vs more serious conditions

Most GLP-1 constipation is uncomfortable but not dangerous. The features that distinguish it from more serious conditions:

• Gradual onset
• Stools still pass, just less frequently and harder than baseline
• Discomfort but no severe pain
• Appetite may be reduced but no persistent vomiting
• No abdominal distension beyond normal

Features that suggest something more serious:

• Complete inability to pass stool or gas
• Severe, progressive abdominal pain
• Visible abdominal distension
• Persistent vomiting, especially of undigested food or bilious material
• Inability to keep liquids down
• Blood in stool or black tarry stool

The serious conditions to consider include ileus (gut paralysis), bowel obstruction, severe gastroparesis, and rarely volvulus or perforation. These have been reported with GLP-1 medications, though rarely. Patients with these features should seek emergency evaluation rather than attempt home laxative management.

Tirzepatide constipation: similar or different?

SURMOUNT-1 reported constipation in:

• 5 mg dose: ~11%
• 10 mg dose: ~14%
• 15 mg dose: ~17%
• Placebo: ~7%

The rates are somewhat lower than semaglutide's 24%, though the trial populations and reporting were not identical. The mechanism is the same (slowed gut transit), and management is identical.

Some patients who experience problematic constipation on semaglutide tolerate tirzepatide better, and vice versa. The variation likely reflects individual sensitivity rather than meaningful drug differences.

Decision framework

Mild constipation (less frequent stools but still passing): Increase hydration to 2 to 3 liters daily, add psyllium 1 tbsp daily, walk after meals. Reassess in 1 week.

Moderate constipation (stools every 3 to 4 days, hard, difficult passage): Continue above plus polyethylene glycol 17 g daily. Reassess in 1 week.

Persistent moderate constipation despite above: Add magnesium citrate 200 to 400 mg at night. Consider occasional rescue with bisacodyl 5 mg.

Severe constipation (no stool for more than 5 to 7 days, abdominal discomfort): Contact prescriber. May need temporary medication pause or prescription motility agent.

Constipation with concerning features (severe pain, distension, vomiting): Emergency evaluation. Rule out ileus or obstruction.

FAQ

Does Ozempic cause constipation? Yes, in about 24% of users on the higher doses.

What is the best treatment? Hydration, fiber, polyethylene glycol (MiraLAX) is the standard combination.

Will it resolve on its own? Usually not while continuing the medication. Active management is typically needed.

Is constipation dangerous? Routine constipation is not dangerous. Severe cases with pain, distension, or vomiting warrant evaluation.

Can I take laxatives daily? Osmotic laxatives like polyethylene glycol are safe for daily long-term use. Stimulant laxatives should be limited to occasional use.

Does fiber make it worse? Fiber without adequate water can worsen constipation. With proper hydration, fiber improves it.

Should I stop Ozempic for constipation? Rarely necessary. Most cases are managed with hydration, fiber, and OTC laxatives.

Will my normal bowel function return after stopping? Yes, typically within 2 to 4 weeks.

Related guides

• Does Ozempic Cause Body Odor? Walking Through the Causation Question Honestly
• Does Ozempic Cause Blindness? The NAION Signal, Honestly Explained
• Does Ozempic Cause Cancer? Separating the Boxed Warning, the Rodent Data, and the Human Evidence
• Does Ozempic Cause Hair Loss? What the Trial Data Actually Shows
• Does Ozempic Cause Diarrhea? When It Happens and Why

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
3. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motility. Exp Diabetes Res. 2011;2011:279530.
4. Bharucha AE, Lacy BE. Mechanisms, Evaluation, and Management of Chronic Constipation. Gastroenterology. 2020;158(5):1232-1249.
5. American Gastroenterological Association. AGA Clinical Practice Guideline on the Pharmacological Management of Chronic Idiopathic Constipation. Gastroenterology. 2023.
6. DiPalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102(7):1436-1441.
7. Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100(1):232-242.
8. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563.
9. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. Most recent revision 2024.
10. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. Most recent revision 2024.
11. Camilleri M, Sellin JH, Barrett KE. Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. Gastroenterology. 2017;152(3):515-532.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform. The content of this article is general education and does not substitute for personalized medical care. Persistent or severe constipation should be evaluated by your prescriber.

Compounded Medication Notice. Compounded semaglutide and tirzepatide formulations are prepared by 503A pharmacies under state regulation. They are not FDA-approved drug products. Side effect profiles may differ from the branded forms.

Results Disclaimer. Constipation severity and response to management strategies vary considerably between patients. The recommendations here describe common approaches; individual care should be tailored.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. MiraLAX is a registered trademark of Bayer Consumer Care AG. FormBlends has no affiliation with these companies.